SURVYR

RNA

Atrium Therapeutics, Inc.
$8.32
+$0.27 (3.35%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-49%-33%-17%-1%+14%Feb 2026Oct 2026Jun 202652w high $16.7752w low $7.49
RNASPY
Wall St. Highest PT $25.00 (+200.5%) Wall St. Avg PT $23.00 (+176.4%)
$8$14$21$28$34POC $13Hi $25Avg $23
Underwater Drawdown %Max DD -54.0%Current -49.7%
0.0%-54.0%
Relative Strength vs SPY-56.7% vs SPYUnderperforming
+71%0%-71%
1W
+$0.34 (4.26%)
1M
+$0.03 (0.36%)
3M
−$3.17 (27.59%)
6M
−$4.23 (33.71%)
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
5 analysts · mean score 1.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$8.32
Average target$23.00
+$14.68 (+176.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$15.00
Median$23.00
High$25.00
12-month Wall Street target range
Recent analyst rating changes · 30
Initiated
2026-10-22 · Roth Capital started covering RNA at Buy
Reiterated
2026-08-14 · HC Wainwright & Co. reiterated Buy on RNA
Initiated
2026-08-06 · HC Wainwright & Co. started covering RNA at Buy
Initiated
2026-06-18 · Cantor Fitzgerald started covering RNA at Overweight
Initiated
2026-05-15 · Leerink Partners started covering RNA at Outperform
Initiated
2026-03-11 · Wells Fargo started covering RNA at Overweight
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$140.3M
P/E (next 12 months, estimated)-1.4
52-week range$7.49 – $16.77
Revenue growth (latest quarter vs a year ago)-21.9%
Dividend yieldNo dividend
Analyst consensusStrong Buy (5)
Average analyst price target$23.00 (+176%)

What they do

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for RNA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

RNA earningsNext report in 12 days
Next report
Mon Nov 9, 2026Time not confirmed
EPS consensus-$0.63 range -$0.67–-$0.59
Revenue consensus$12.0M 5 analysts
Last 4 quarters · EPS vs estimate
Aug 13, 2026-$1.18est -$0.64−84.4%Below estimates
May 14, 2026-$0.97est -$1.05+7.6%Above estimates
Feb 23, 2026-$1.59est -$1.26−26.4%Below estimates
Nov 10, 2025-$1.27est -$1.10−15.3%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-23 23:30:17 ET
24-1125-0225-0525-0825-1126-0226-0526-08-1.590.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$3.0M-21.9%
2026-03-31$19.6M–
2025-12-31$859.0K–
2025-09-30$12.3M–
2025-06-30$3.8M–

News & catalysts

More news
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
PR Newswire · Oct 27
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · Oct 20
Rating changes
Initiated
2026-10-22 · Roth Capital started covering RNA at Buy
Reiterated
2026-08-14 · HC Wainwright & Co. reiterated Buy on RNA
Initiated
2026-08-06 · HC Wainwright & Co. started covering RNA at Buy
Initiated
2026-06-18 · Cantor Fitzgerald started covering RNA at Overweight
Initiated
2026-05-15 · Leerink Partners started covering RNA at Outperform
Initiated
2026-03-11 · Wells Fargo started covering RNA at Overweight

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-23 23:30:17 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026